Jean Nichols

3.3k total citations · 1 hit paper
50 papers, 2.1k citations indexed

About

Jean Nichols is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Jean Nichols has authored 50 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Immunology, 20 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Jean Nichols's work include Toxin Mechanisms and Immunotoxins (19 papers), Histone Deacetylase Inhibitors Research (12 papers) and Transgenic Plants and Applications (12 papers). Jean Nichols is often cited by papers focused on Toxin Mechanisms and Immunotoxins (19 papers), Histone Deacetylase Inhibitors Research (12 papers) and Transgenic Plants and Applications (12 papers). Jean Nichols collaborates with scholars based in United States, Australia and United Kingdom. Jean Nichols's co-authors include John R. Murphy, Joel B. Baseman, H. Miles Prince, Barbara Balser, Terry B. Strom, Francine M. Foss, Barbara Pro, Sarah McCue Horwitz, Bertrand Coiffier and Matthew Greenwood and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jean Nichols

50 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jean Nichols

Since Specialization

Citations

This map shows the geographic impact of Jean Nichols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Nichols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Nichols more than expected).

Fields of papers citing papers by Jean Nichols

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Nichols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Nichols. The network helps show where Jean Nichols may publish in the future.

Co-authorship network of co-authors of Jean Nichols

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Nichols. A scholar is included among the top collaborators of Jean Nichols based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Nichols. Jean Nichols is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy breakdown → 2012 ·Journal of Clinical Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz	485
2	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin 2012 ·Leukemia & lymphoma ·Youn H. Kim, Marie‐France Demierre, Ellen J. Kim, Adam Lerner, Alain H. Rook, Madeleine Duvic, Tadeusz Robak, А. В. Самцов, William McCulloch, Suephy C. Chen, Joel Waksman, Jean Nichols, Sean Whittaker	35
3	Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition 2009 ·PubMed ·Ariella B. Hanker, Kevin D. Healy, Jean Nichols, Channing J. Der	5
4	Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®) 2002 ·Clinical Lymphoma ·Madeleine Duvic, Timothy M. Kuzel, Elise A. Olsen, Ann Martin, Francine M. Foss, Youn H. Kim, Peter Heald, Patricia Bacha, Jean Nichols, Astra M. Liepa	85
5	Diphtheria Toxin Fusion Proteins 1998 ·Current topics in microbiology and immunology ·Francine M. Foss, Mansoor N. Saleh, James G. Krueger, Jean Nichols, John R. Murphy	40
6	Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial 1998 ·Journal of the American Academy of Dermatology ·Jerry Bagel, (unknown), Debra Breneman, Michael F. Holick, Thomas Littlejohn, (unknown), (unknown), David Fivenson, Jean Nichols	73
7	Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides 1998 ·Journal of the American Academy of Dermatology ·Mansoor N. Saleh, CF LeMaistre, Timothy M. Kuzel, Francine M. Foss, Leonidas C. Platanias, Gary N. Schwartz, Mark J. Ratain, Alain H. Rook, César O. Freytes, Fiona E. Craig, James M. Reuben, (unknown), Jean Nichols	99
8	Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis 1996 ·Atherosclerosis ·D.Douglas Miller, Richard G. Bach, Fermin O. Tio, Steven R. Bailey, Cory A. Waters, Thasia Woodworth, Jean Nichols, (unknown), (unknown)	5
9	Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. 1993 ·Journal of Clinical Investigation ·J. Geoffrey Pickering, (unknown), L Weir, (unknown), Jean Nichols, Jeffrey M. Isner	37
10	DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival. 1993 ·PubMed ·Debra A. Hullett, (unknown), Devin E. Eckhoff, Jean Nichols, Elsie M. Eugui, A. C. Allison, H W Sollinger	2
11	Recombinant fusion toxins — A new class of targeted biologic therapeutics 1993 ·Cancer treatment and research ·Thasia Woodworth, Jean Nichols	12
12	Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB₄₈₆IL‐2) in rat adjuvant arthritis 1992 ·European Journal of Immunology ·Patricia Bacha, (unknown), Stuart J. Perper, David E. Trentham, Jean Nichols	23
13	Interleukin 2 receptor targeted fusion toxin (DAB₄₈₆‐IL‐2) treatment blocks diabetogenic autoimmunity in non‐obese diabetic mice 1992 ·European Journal of Immunology ·Álvaro Pacheco‐Silva, (unknown), (unknown), O. Pankewycz, Jean Nichols, John R. Murphy, (unknown), Vicki E. Rubin‐Kelley	35
14	Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443 1992 ·PubMed ·Debra A. Hullett, (unknown), (unknown), Jean Nichols, Elsie M. Eugui, A. C. Allison, Hans W. Sollinger	1
15	Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies 1991 ·Journal of Neuroimmunology ·Laura J. Balcer, Kevin R. McIntosh, Jean Nichols, Daniel B. Drachman	12
16	Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein 1991 ·Cellular Immunology ·Alan P. Grailer, Jean Nichols, Terry B. Strom, Hans W. Sollinger, William J. Burlingham	4
17	Impact of interleukin‐2‐receptor‐targeted cytotoxins on a unique model of murine interleukin‐2‐receptor‐expressing malignancy 1991 ·International Journal of Cancer ·(unknown), (unknown), Donna McCarthy, (unknown), Gen Yamada, Jean Nichols	25
18	Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor 1990 ·International Journal of Cancer ·(unknown), Silvia E. Hajos, John R. Murphy, Terry B. Strom, Jean Nichols, (unknown), David Naor	23
19	Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells 1990 ·European Journal of Immunology ·Cory A. Waters, (unknown), Catherine E. Snider, Kyogo Itoh, Kendall A. Smith, Jean Nichols, Terry B. Strom, John R. Murphy	95
20	Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models 1990 ·Cancer Chemotherapy and Pharmacology ·Patricia Bacha, (unknown), Nasim Kassam, (unknown), Donna E. Akiyoshi, Cory A. Waters, Jean Nichols, Michael G. Rosenblum	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact